Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Isentress
Raltegravir is an integrase strand transfer inhibitor (INSTI) used in combination with other antiretroviral medications to treat HIV-1 infection in adults and children. It works by blocking the enzyme integrase, which HIV needs to insert its genetic material into human cells. This prevents the virus from replicating and spreading within the body. Raltegravir is generally well-tolerated, but some common side effects include diarrhea, nausea, and headache. It's important to note that raltegravir does not cure HIV, but helps manage the infection and slow its progression.
For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Outcome:
Decreased raltegravir levels, potentially leading to treatment failure.
Mechanism:
Induction of drug-metabolizing enzymes.
Outcome:
Slightly decreased raltegravir levels.
Mechanism:
Altered gastric pH.
Outcome:
Potential for slightly decreased raltegravir absorption.
Mechanism:
Unknown.
Most likely new formulation: Long-acting injectable formulation (Year: 2025, 75% confidence)
Based on current usage trends and clinical trial data, raltegravir is expected to maintain its current regulatory status with a high likelihood (>90%) of continued approval for HIV treatment.
Antiretroviral, Integrase Inhibitor
Integrase strand transfer inhibitor